Guardian Pharmacy Services (NYSE:GRDN) Stock Price Down 5.5% – Should You Sell?

Guardian Pharmacy Services, Inc. (NYSE:GRDN) shares dropped 5.5% during mid-day trading on Tuesday . The stock traded as low as $39.54 and last traded at $39.1860. 121,588 shares traded hands during trading, a decline of 69% from the average session volume of 388,726 shares. The stock had previously closed at $41.47.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Oppenheimer upped their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of Guardian Pharmacy Services from a “hold” rating to a “buy” rating in a research report on Sunday. Truist Financial increased their price target on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Weiss Ratings upgraded Guardian Pharmacy Services from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 6th. Finally, Bank of America upped their price target on Guardian Pharmacy Services from $42.00 to $47.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Guardian Pharmacy Services has an average rating of “Moderate Buy” and an average target price of $43.83.

Guardian Pharmacy Services Price Performance

The stock’s 50 day moving average is $40.95 and its two-hundred day moving average is $37.38. The stock has a market capitalization of $1.92 billion, a PE ratio of 37.44, a price-to-earnings-growth ratio of 2.06 and a beta of 0.10.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. The company had revenue of $351.77 million during the quarter, compared to the consensus estimate of $340.45 million. On average, equities analysts predict that Guardian Pharmacy Services, Inc. will post 1.18 earnings per share for the current year.

Hedge Funds Weigh In On Guardian Pharmacy Services

Several hedge funds have recently added to or reduced their stakes in GRDN. Ameritas Investment Partners Inc. raised its stake in Guardian Pharmacy Services by 26.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after acquiring an additional 345 shares in the last quarter. California State Teachers Retirement System boosted its stake in Guardian Pharmacy Services by 3.4% in the fourth quarter. California State Teachers Retirement System now owns 17,983 shares of the company’s stock valued at $541,000 after acquiring an additional 593 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in Guardian Pharmacy Services by 20.4% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,070 shares of the company’s stock valued at $183,000 after acquiring an additional 1,028 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Guardian Pharmacy Services by 13.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,885 shares of the company’s stock worth $358,000 after purchasing an additional 1,409 shares during the last quarter. Finally, Clearstead Advisors LLC grew its holdings in shares of Guardian Pharmacy Services by 196.3% during the fourth quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock worth $79,000 after purchasing an additional 1,741 shares during the last quarter.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.